12/19
09:07 am
alxo
Yahoo Finance [Yahoo! Finance]
High
Report
Yahoo Finance [Yahoo! Finance]
12/19
07:42 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
High
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
12/18
09:19 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/18
08:14 am
alxo
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium [Yahoo! Finance]
Low
Report
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium [Yahoo! Finance]
12/18
08:07 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
12/18
08:00 am
alxo
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
Low
Report
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
12/12
08:17 am
alxo
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 [Yahoo! Finance]
Medium
Report
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 [Yahoo! Finance]
12/12
08:00 am
alxo
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
Low
Report
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
12/10
09:07 am
alxo
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer [Yahoo! Finance]
Medium
Report
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer [Yahoo! Finance]
12/10
09:00 am
alxo
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Medium
Report
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
11/26
08:00 am
alxo
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
Low
Report
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/21
09:10 am
alxo
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors [Yahoo! Finance]
Medium
Report
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors [Yahoo! Finance]
11/14
08:12 am
alxo
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer [Yahoo! Finance]
Low
Report
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer [Yahoo! Finance]
11/14
08:00 am
alxo
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Low
Report
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
11/12
09:03 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/7
04:00 pm
alxo
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/4
08:00 am
alxo
ALX Oncology Announces November Investor Conference Participation
Neutral
Report
ALX Oncology Announces November Investor Conference Participation
11/1
05:33 pm
alxo
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 [Yahoo! Finance]
Low
Report
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 [Yahoo! Finance]
11/1
05:30 pm
alxo
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Neutral
Report
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
10/8
05:35 pm
alxo
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight [Yahoo! Finance]